NovoCure Limited (NASDAQ:NVCR) Files An 8-K Results of Operations and Financial Condition

Item 2.02Results of Operations and Financial Condition

On April 27, 2017, the Company issued a press release announcing
certain financial results for the quarter ended March 31, 2017.A
copy of the press release is attached hereto as Exhibit 99.1.

The information contained in this Current Report shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing.

Item 9.01Financial Statements and Exhibits

(d)Exhibits

About NovoCure Limited (NASDAQ:NVCR)

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

NovoCure Limited (NASDAQ:NVCR) Recent Trading Information

NovoCure Limited (NASDAQ:NVCR) closed its last trading session up +0.15 at 10.95 with 709,109 shares trading hands.